Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rosuvastatin · Crestor, Ezallor Sprinkle

Small molecule · Inhibitor of HMG-CoA reductase (HMGCR) · developed by Astrazeneca

Approved FDA, Aug 2003
AZN Developer
18 Registered trials

What is Rosuvastatin?

Rosuvastatin is a statin that selectively and competitively inhibits HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol. It lowers hepatic cholesterol and increases LDL cholesterol uptake.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Crestor, Ezallor Sprinkle, CRESTOR
Drug type
Small molecule
Targets
HMG-CoA reductase (HMGCR)
Mechanism
Inhibitor of HMG-CoA reductase (HMGCR)
Pathways
cholesterol biosynthesis, mevalonate pathway, isoprenylation of Ras and Rho GTPases
Therapy area
Metabolic
Developer
Astrazeneca (AZN)
Also in trials of
ALGS, ARDX, ARVN, AVIR, BCRX, COLL, ENTA, LKFT, LLY, LXRX
FDA status
Approved as Crestor, Ezallor Sprinkle (August 12, 2003), NDA021366

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02772640 Phase 4 Hypercholesterolemia Completed COLL
NCT07930507 Phase 3 Hypercholesterolemia Not yet recruiting AZN
NCT07216482 Phase 3 Hyperlipidemia Completed MRK
NCT06834932 Phase 2/3 Dyslipidaemia Active not recruiting AZN
NCT07820891 Phase 1 Healthy Adult Participants Recruiting ONC
NCT07534592 Phase 1 Healthy Participants Active not recruiting AZN
NCT07372625 Phase 1 TP53 Y220C Mutation Recruiting PMVP
NCT07339722 Phase 1 Healthy Recruiting LLY
NCT06917508 Phase 1 RSV Infection Completed ENTA
NCT06717269 Phase 1 Healthy Volunteer Completed NRIX
NCT06191991 Phase 1 Healthy Volunteers Completed ALGS
NCT05652660 Phase 1 Healthy Completed ARVN
NCT05154123 Phase 1 Healthy Volunteer Study Completed AVIR
NCT04608344 Phase 1 Rheumatoid Arthritis Completed LKFT
NCT03136237 Phase 1 Hereditary Angioedema Completed BCRX
NCT02542969 Phase 1 Healthy Completed MDGL
NCT02300363 Phase 1 Healthy Completed LXRX
NCT02140281 Phase 1 Healthy Volunteers Completed ARDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsDyslipidaemiaHealthy Adult ParticipantsHealthy ParticipantsTP53 Y220C MutationCystic FibrosisDrug Drug InteractionHealthyHealthy VolunteerHealthy Volunteer StudyHereditary AngioedemaHypercholesterolemiaRheumatoid ArthritisRSV Infection

Other drugs acting on HMGCR

More from Astrazeneca

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Rosuvastatin

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.